Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 23, Issue 5, Pages 599-610
Publisher
Informa Healthcare
Online
2014-03-05
DOI
10.1517/13543784.2014.895323
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pazopanib Inhibits the Activation of PDGFRβ-Expressing Astrocytes in the Brain Metastatic Microenvironment of Breast Cancer Cells
- (2013) Brunilde Gril et al. AMERICAN JOURNAL OF PATHOLOGY
- Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer
- (2013) Giuseppe Curigliano et al. BREAST
- A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer
- (2013) Stephen R. D. Johnston et al. BREAST CANCER RESEARCH AND TREATMENT
- A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer
- (2013) Erica L. Mayer et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
- (2013) F. Andre et al. CLINICAL CANCER RESEARCH
- Therapeutic targeting of platelet-derived growth factor receptors in solid tumors
- (2013) Monika Ehnman et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial
- (2013) José Baselga et al. Trials
- Contrasting effects of sunitinib within in vivo models of metastasis
- (2012) Jonathan C. Welti et al. ANGIOGENESIS
- Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer
- (2012) M. T. Weigel et al. ANNALS OF ONCOLOGY
- Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer
- (2012) Jonas Bergh et al. BREAST
- Phase II open-label study of sunitinib in patients with advanced breast cancer
- (2012) Denise A. Yardley et al. BREAST CANCER RESEARCH AND TREATMENT
- Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
- (2012) Libero Santarpia et al. BREAST CANCER RESEARCH AND TREATMENT
- Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway
- (2012) Vesselina G. Cooke et al. CANCER CELL
- An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
- (2012) Hajime Asahina et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer
- (2012) William J. Gradishar et al. EUROPEAN JOURNAL OF CANCER
- Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
- (2012) Maja J. A. de Jonge et al. INVESTIGATIONAL NEW DRUGS
- Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer
- (2012) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors
- (2012) Alicia S Chung et al. JOURNAL OF PATHOLOGY
- Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression
- (2011) Newton J. Hurst et al. BIOCHEMICAL JOURNAL
- Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
- (2011) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- RETRACTED ARTICLE: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-κB signaling pathways
- (2010) Aamir Ahmad et al. BREAST CANCER RESEARCH AND TREATMENT
- Pazopanib Reveals a Role for Tumor Cell B-Raf in the Prevention of HER2+ Breast Cancer Brain Metastasis
- (2010) B. Gril et al. CLINICAL CANCER RESEARCH
- The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness
- (2010) Zhiwei Wang et al. CURRENT DRUG TARGETS
- Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases
- (2010) Maximilian Merz et al. EUROPEAN JOURNAL OF CANCER
- Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors
- (2010) A. R. Tan et al. ONCOLOGIST
- A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium
- (2010) S. K. Taylor et al. ONCOLOGIST
- Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast Cancer
- (2009) Janna Paulsson et al. AMERICAN JOURNAL OF PATHOLOGY
- An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer
- (2009) M. Kozloff et al. ANNALS OF ONCOLOGY
- PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
- (2009) Yongping Crawford et al. CANCER CELL
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Phase I Trial of Pazopanib in Patients with Advanced Cancer
- (2009) H. I. Hurwitz et al. CLINICAL CANCER RESEARCH
- Pazopanib: therapeutic developments
- (2009) Suwicha Limvorasak et al. EXPERT OPINION ON PHARMACOTHERAPY
- Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR- : clinical activity and biological correlations
- (2008) M. Cristofanilli et al. ANNALS OF ONCOLOGY
- PDGF-BB is a Novel Prognostic Factor in Colorectal Cancer
- (2008) Yoshito Nakamura et al. ANNALS OF SURGICAL ONCOLOGY
- Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer
- (2008) Louis Wing-Cheong Chow et al. CANCER LETTERS
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Role of platelet-derived growth factors in physiology and medicine
- (2008) J. Andrae et al. GENES & DEVELOPMENT
- Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2008) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting
- (2008) Kristian Pietras et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search